SV

Street Verdict

Analyst Scorecard

A record of what ETMarkets Analysis said publicly, with the source. Not advice.

“Short-term traders can consider buying Dr. Reddy’s Laboratories, targeting Rs 1,360 within 1-2 months. The stock broke out from a 5-week consolidation in September 2025 with encouraging volumes, suggesting the rally may continue. Immediate resistance is around Rs 1,320–1,340, with strong support at Rs 1,260–1,240.”

ETMarkets Analysis’s track record (trackable calls only): 193 graded calls · 95% CI 23–35%

Dr. Reddy's Laboratories Ltd.BullishCalled 10 Sep 2025Graded 10 Nov 2025
Verdict:MISS

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.

No entry price is stated, so the call starts at the first close after it was published.

Target ₹1,360, as stated.

Window: 60 days, the time frame the call states ("1-2 months").

Neither the target ₹1,360 was reached on a close by the end of the window. Miss.

The grader’s working: R4 TARGET_CALL: entered ₹1316.7 on 2025-09-12 (next trading session's close); neither target nor stop reached by window end 2025-11-10. Window 60 days — rule H1: the quote states "1-2 months".

How it played out

How this is worked out
Time to target
The target was not reached on a close inside the window.
Worst close against it
The closing price went as far as 9.17% against the call up to 10 Nov 2025, when the call was decided, measured from the entry price. Closing prices only; an intraday dip is never counted.

From the entry the grade used, on closing prices. This is a record of one past call and is not advice.

Tracking Dr. Reddy's Laboratories Ltd. since this call

1-year tracking window
Read the original articleSee ETMarkets Analysis’s full track record